Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's Neutron delay looks like a manufacturing issue, not a flawed design. Rocket Lab says it identified and mitigated dome voids, but this second setback delays launch revenue; first flight could slip to mid-2027 or later if testing finds more issues. Space Systems is about 81% of revenue and backlog is around $2.4B, sustaining the business as Neutron develops. Rocket Lab could still become a megacap over the next decade. x.com 

Rocket Lab's only 'moat' was Neutron, and its reported launch delay now amounts to cancellation for the investment case. The quoted report puts its inaugural launch in 2027; $2.99 is floated as a possible share price. x.com 

Rocket Lab still looks ridiculously expensive at 29 times forward sales against SpaceX at 22 times, even after a 65% fall. At 22 times, Rocket Lab would be roughly $38, and SpaceX would still be the pick. SpaceX also has better forward guidance; Rocket Lab's negative adjusted EBITDA makes sales multiples the valuation yardstick. x.com  x.com  x.com  x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Rocket Lab's government awards and backlog look priced in, while the costs of Neutron do not. Its space-beta monopoly has ended with SpaceX's listing, and it needs to max out R&D to accelerate Neutron before its maiden flight. A brand-new rocket, a new methalox engine and a new launch site burning more money mean weak earnings the market has apparently not priced. x.com  x.com 

Rocket Lab's Neutron delay could drag public space stocks down because the space basket usually trades together. Rocket Lab is likely to pull AST SpaceMobile down with it, especially in a bad market. The delay also pushes back a possible AST launch on Neutron, though that launch was not expected and the news is not necessarily bad for AST directly. x.com  x.com  x.com 

Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.com 

Rocket Lab could face a difficult 9-12 months because much of the space industry's future is already priced into equity valuations, even as its business and backlog grow. A monthly close below the $61 21-month EMA would raise the risk that the uptrend has ended and shift attention toward $35-45 for a better long-term entry; holding $61 preserves a more constructive reading. The company could still trade considerably higher over a longer horizon. x.com